Marijuana Research Today is a free monthly online journal that collates and summarizes the latest research about Marijuana, including details on benefits, cancer, effects, uses, addiction.

Volume 7 (2010), Issue 12 (December)

1. Degree of urbanization and gender differences in substance use among Slovak adolescents.
   Int J Public Health. [Abstract] [Full-text]
2. The prevalence of work-related deaths associated with alcohol and drugs in Victoria, Australia, 2001-6.
   Inj Prev, 16(6): 423-8. [Abstract] [Full-text]
3. Degree of urbanization and gender differences in substance use among Slovak adolescents.
   Int J Public Health. [Abstract] [Full-text]
4. The prevalence of work-related deaths associated with alcohol and drugs in Victoria, Australia, 2001-6.
   Inj Prev, 16(6): 423-8. [Abstract] [Full-text]
5. Prescribing of controlled medications to adolescents and young adults in the United States.
   Pediatrics, 126(6): 1108-16. [Abstract] [Full-text]
6. Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency.
   Prog Neuropsychopharmacol Biol Psychiatry. [Abstract] [Full-text]
7. Prescribing of controlled medications to adolescents and young adults in the United States.
   Pediatrics, 126(6): 1108-16. [Abstract] [Full-text]
8. When to Intervene: Elementary School, Middle School or Both? Effects of keepin' It REAL on Substance Use Trajectories of Mexican Heritage Youth.
   Prev Sci. [Abstract] [Full-text]
9. Decriminalization of Cannabis - potential risks for children?
   Acta Paediatr. [Abstract] [Full-text]
10. Modulation of risk-taking in marijuana users by transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC).
    Drug Alcohol Depend, 112(3): 220-5. [Abstract] [Full-text]
11. Self-control and its relation to joint developmental trajectories of cannabis use and depressive mood symptoms.
    Drug Alcohol Depend, 112(3): 201-8. [Abstract] [Full-text]
12. When to Intervene: Elementary School, Middle School or Both? Effects of keepin' It REAL on Substance Use Trajectories of Mexican Heritage Youth.
    Prev Sci. [Abstract] [Full-text]
13. Modulation of risk-taking in marijuana users by transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC).
    Drug Alcohol Depend, 112(3): 220-5. [Abstract] [Full-text]
14. Self-control and its relation to joint developmental trajectories of cannabis use and depressive mood symptoms.
    Drug Alcohol Depend, 112(3): 201-8. [Abstract] [Full-text]
15. Cannabis and the lung.
    J R Coll Physicians Edinb, 40(4): 328-34. [Abstract] [Full-text]
16. Pediatric cannabinoid hyperemesis: two cases.
    Pediatr Emerg Care, 26(12): 919-20. [Abstract] [Full-text]
17. An initial trial of a computerized behavioral intervention for cannabis use disorder.
    Drug Alcohol Depend. [Abstract] [Full-text]
18. Cannabinoids lead to enhanced virulence of the smallpox vaccine (vaccinia) virus.
    Immunobiology. [Abstract] [Full-text]
19. Substance use, childhood traumatic experience, and Posttraumatic Stress Disorder in an urban civilian population.
    Depress Anxiety, 27(12): 1077-86. [Abstract] [Full-text]
20. Cannabis and the lung.
    J R Coll Physicians Edinb, 40(4): 328-34. [Abstract] [Full-text]
21. Pediatric cannabinoid hyperemesis: two cases.
    Pediatr Emerg Care, 26(12): 919-20. [Abstract] [Full-text]
22. An initial trial of a computerized behavioral intervention for cannabis use disorder.
    Drug Alcohol Depend. [Abstract] [Full-text]
23. Substance use, childhood traumatic experience, and Posttraumatic Stress Disorder in an urban civilian population.
    Depress Anxiety, 27(12): 1077-86. [Abstract] [Full-text]
24. A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis.
    J Subst Abuse Treat, 40(1): 95-101. [Abstract] [Full-text]
25. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
26. Developmental trajectories of psychotic-like experiences across adolescence: impact of victimization and substance use.
    Psychol Med, 41(1): 47-58. [Abstract] [Full-text]
27. A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis.
    J Subst Abuse Treat, 40(1): 95-101. [Abstract] [Full-text]
28. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
29. Developmental trajectories of psychotic-like experiences across adolescence: impact of victimization and substance use.
    Psychol Med, 41(1): 47-58. [Abstract] [Full-text]
30. A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis.
    J Subst Abuse Treat, 40(1): 95-101. [Abstract] [Full-text]
31. Psychiatric 'diseases' versus behavioral disorders and degree of genetic influence.
    Psychol Med, 41(1): 33-40. [Abstract] [Full-text]
32. Developmental trajectories of psychotic-like experiences across adolescence: impact of victimization and substance use.
    Psychol Med, 41(1): 47-58. [Abstract] [Full-text]
33. Recreational drug abuse in patients hospitalized for diabetic ketosis or diabetic ketoacidosis.
    Acta Diabetol. [Abstract] [Full-text]
34. Self-rated health status in an urban indigenous primary care setting: implications for clinicians and public health policy.
    Aust N Z J Public Health, 34(6): 598-601. [Abstract] [Full-text]
35. Neural correlates of verbal learning in adolescent alcohol and marijuana users.
    Addiction. [Abstract] [Full-text]
36. Medical cannabis and chronic opioid therapy.
    J Pain Palliat Care Pharmacother, 24(4): 356-61. [Abstract] [Full-text]
37. Recreational drug abuse in patients hospitalized for diabetic ketosis or diabetic ketoacidosis.
    Acta Diabetol. [Abstract] [Full-text]
38. Self-rated health status in an urban indigenous primary care setting: implications for clinicians and public health policy.
    Aust N Z J Public Health, 34(6): 598-601. [Abstract] [Full-text]
39. Neural correlates of verbal learning in adolescent alcohol and marijuana users.
    Addiction. [Abstract] [Full-text]
40. Medical cannabis and chronic opioid therapy.
    J Pain Palliat Care Pharmacother, 24(4): 356-61. [Abstract] [Full-text]
41. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study.
    Eur Addict Res, 17(1): 37-43. [Abstract] [Full-text]
42. Recreational drug abuse in patients hospitalized for diabetic ketosis or diabetic ketoacidosis.
    Acta Diabetol. [Abstract] [Full-text]
43. Neural correlates of verbal learning in adolescent alcohol and marijuana users.
    Addiction. [Abstract] [Full-text]
44. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study.
    Eur Addict Res, 17(1): 37-43. [Abstract] [Full-text]
45. Agreement between maternal cannabis use during pregnancy according to self-report and urinalysis in a population-based cohort: the Generation R Study.
    Eur Addict Res, 17(1): 37-43. [Abstract] [Full-text]
46. Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample.
    Psychopharmacology (Berl). [Abstract] [Full-text]
47. Riskier Sexual Partners Contribute to the Increased Rate of Sexually Transmitted Diseases Among Youth With Substance Use Disorders.
    Sex Transm Dis. [Abstract] [Full-text]
48. Health Effects of Using Cannabis for Therapeutic Purposes: A Gender Analysis of Users' Perspectives.
    Subst Use Misuse. [Abstract] [Full-text]
49. "Bong lung" in cystic fibrosis: a case report.
    J Med Case Reports, 4: 371. [Abstract] [Full-text]
50. Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample.
    Psychopharmacology (Berl). [Abstract] [Full-text]
51. Riskier Sexual Partners Contribute to the Increased Rate of Sexually Transmitted Diseases Among Youth With Substance Use Disorders.
    Sex Transm Dis. [Abstract] [Full-text]
52. Health Effects of Using Cannabis for Therapeutic Purposes: A Gender Analysis of Users' Perspectives.
    Subst Use Misuse. [Abstract] [Full-text]
53. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care.
    Acta Psychiatr Scand, 123(1): 21-7. [Abstract] [Full-text]
54. Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample.
    Psychopharmacology (Berl). [Abstract] [Full-text]
55. Riskier Sexual Partners Contribute to the Increased Rate of Sexually Transmitted Diseases Among Youth With Substance Use Disorders.
    Sex Transm Dis. [Abstract] [Full-text]
56. Health Effects of Using Cannabis for Therapeutic Purposes: A Gender Analysis of Users' Perspectives.
    Subst Use Misuse. [Abstract] [Full-text]
57. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care.
    Acta Psychiatr Scand, 123(1): 21-7. [Abstract] [Full-text]
58. Cannabis use and non-clinical dimensions of psychosis in university students presenting to primary care.
    Acta Psychiatr Scand, 123(1): 21-7. [Abstract] [Full-text]
59. Disruption of Frontal Theta Coherence by Δ(9)-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms.
    Neuropsychopharmacology. [Abstract] [Full-text]
60. Posttraumatic stress and marijuana use coping motives: The mediating role of distress tolerance.
    J Anxiety Disord. [Abstract] [Full-text]
61. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention.
    J Hepatol. [Abstract] [Full-text]
62. Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.
    J Hepatol. [Abstract] [Full-text]
63. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
    Drug Alcohol Depend. [Abstract] [Full-text]
64. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
    J Am Coll Cardiol, 56(25): 2115-25. [Abstract] [Full-text]
65. Externalizing behaviors and cigarette smoking as predictors for use of illicit drugs: a longitudinal study among finnish adolescent twins.
    Twin Res Hum Genet, 13(6): 550-8. [Abstract] [Full-text]
66. Examining gender differences in substance use and age of first use among rural Appalachian drug users in Kentucky.
    Am J Drug Alcohol Abuse. [Abstract] [Full-text]
67. Cue reactivity in cannabis-dependent adolescents.
    Psychol Addict Behav. [Abstract] [Full-text]
68. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users.
    Anal Bioanal Chem. [Abstract] [Full-text]
69. Alternative therapy in glaucoma management: is there any role?
    Indian J Ophthalmol, 59: S158-60. [Abstract] [Full-text]
70. Disruption of Frontal Theta Coherence by Δ(9)-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms.
    Neuropsychopharmacology. [Abstract] [Full-text]
71. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention.
    J Hepatol. [Abstract] [Full-text]
72. Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.
    J Hepatol. [Abstract] [Full-text]
73. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
    Drug Alcohol Depend. [Abstract] [Full-text]
74. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
    J Am Coll Cardiol, 56(25): 2115-25. [Abstract] [Full-text]
75. Externalizing behaviors and cigarette smoking as predictors for use of illicit drugs: a longitudinal study among finnish adolescent twins.
    Twin Res Hum Genet, 13(6): 550-8. [Abstract] [Full-text]
76. Examining gender differences in substance use and age of first use among rural Appalachian drug users in Kentucky.
    Am J Drug Alcohol Abuse. [Abstract] [Full-text]
77. Cue reactivity in cannabis-dependent adolescents.
    Psychol Addict Behav. [Abstract] [Full-text]
78. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users.
    Anal Bioanal Chem. [Abstract] [Full-text]
79. Common and drug-specific genetic influences on subjective effects to alcohol, tobacco and marijuana use.
    Addiction, 106(1): 215-24. [Abstract] [Full-text]
80. Paternal incarceration and trajectories of marijuana and other illegal drug use from adolescence into young adulthood: evidence from longitudinal panels of males and females in the United States.
    Addiction, 106(1): 121-32. [Abstract] [Full-text]
81. Mephedrone, new kid for the chop?
    Addiction, 106(1): 154-61. [Abstract] [Full-text]
82. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?
    Neurosci Biobehav Rev, 35(3): 377-406. [Abstract] [Full-text]
83. Alternative therapy in glaucoma management: is there any role?
    Indian J Ophthalmol, 59: S158-60. [Abstract] [Full-text]
84. Disruption of Frontal Theta Coherence by Δ(9)-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms.
    Neuropsychopharmacology. [Abstract] [Full-text]
85. Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C.
    J Hepatol. [Abstract] [Full-text]
86. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).
    Drug Alcohol Depend. [Abstract] [Full-text]
87. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.
    J Am Coll Cardiol, 56(25): 2115-25. [Abstract] [Full-text]
88. Examining gender differences in substance use and age of first use among rural Appalachian drug users in Kentucky.
    Am J Drug Alcohol Abuse. [Abstract] [Full-text]
89. Cue reactivity in cannabis-dependent adolescents.
    Psychol Addict Behav. [Abstract] [Full-text]
90. Common and drug-specific genetic influences on subjective effects to alcohol, tobacco and marijuana use.
    Addiction, 106(1): 215-24. [Abstract] [Full-text]
91. Paternal incarceration and trajectories of marijuana and other illegal drug use from adolescence into young adulthood: evidence from longitudinal panels of males and females in the United States.
    Addiction, 106(1): 121-32. [Abstract] [Full-text]
92. Mephedrone, new kid for the chop?
    Addiction, 106(1): 154-61. [Abstract] [Full-text]
93. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?
    Neurosci Biobehav Rev, 35(3): 377-406. [Abstract] [Full-text]
94. Alternative therapy in glaucoma management: is there any role?
    Indian J Ophthalmol, 59: S158-60. [Abstract] [Full-text]
95. Common and drug-specific genetic influences on subjective effects to alcohol, tobacco and marijuana use.
    Addiction, 106(1): 215-24. [Abstract] [Full-text]
96. Paternal incarceration and trajectories of marijuana and other illegal drug use from adolescence into young adulthood: evidence from longitudinal panels of males and females in the United States.
    Addiction, 106(1): 121-32. [Abstract] [Full-text]
97. Mephedrone, new kid for the chop?
    Addiction, 106(1): 154-61. [Abstract] [Full-text]
98. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?
    Neurosci Biobehav Rev, 35(3): 377-406. [Abstract] [Full-text]
99. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.
    J Am Acad Child Adolesc Psychiatry, 50(1): 9-21. [Abstract] [Full-text]
100. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.
     J Am Acad Child Adolesc Psychiatry, 50(1): 9-21. [Abstract] [Full-text]
101. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.
     J Am Acad Child Adolesc Psychiatry, 50(1): 9-21. [Abstract] [Full-text]
102. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses.
     J Am Acad Child Adolesc Psychiatry, 50(1): 9-21. [Abstract] [Full-text]
103. Mental Health and Substance Abuse Characteristics Among a Clinical Sample of Urban American Indian/Alaska Native Youths in a Large California Metropolitan Area: a Descriptive Study.
     Community Ment Health J. [Abstract] [Full-text]
104. Epidemiological analysis of doping offences in the professional tennis circuit.
     J Occup Med Toxicol, 5(1): 30. [Abstract] [Full-text]
105. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis.
     J Ethnopharmacol. [Abstract] [Full-text]
106. Mental Health and Substance Abuse Characteristics Among a Clinical Sample of Urban American Indian/Alaska Native Youths in a Large California Metropolitan Area: a Descriptive Study.
     Community Ment Health J. [Abstract] [Full-text]
107. Mental Health and Substance Abuse Characteristics Among a Clinical Sample of Urban American Indian/Alaska Native Youths in a Large California Metropolitan Area: a Descriptive Study.
     Community Ment Health J. [Abstract] [Full-text]
108. Caller satisfaction with the Cannabis Information and Helpline.
     J Telemed Telecare. [Abstract] [Full-text]
109. Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment.
     Drug Alcohol Depend. [Abstract] [Full-text]
110. Caller satisfaction with the Cannabis Information and Helpline.
     J Telemed Telecare. [Abstract] [Full-text]
111. Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment.
     Drug Alcohol Depend. [Abstract] [Full-text]
112. Caller satisfaction with the Cannabis Information and Helpline.
     J Telemed Telecare. [Abstract] [Full-text]
113. Validation of the Cannabis Expectancy Questionnaire (CEQ) in adult cannabis users in treatment.
     Drug Alcohol Depend. [Abstract] [Full-text]
114. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy.
     Arch Gynecol Obstet. [Abstract] [Full-text]
115. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
     Pharmacol Biochem Behav. [Abstract] [Full-text]
116. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences.
     Psychiatry Res, 191(1): 51-9. [Abstract] [Full-text]
117. Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice.
     Behav Brain Res. [Abstract] [Full-text]
118. Pain-related anxiety and marijuana use motives: a pilot test among active marijuana-using young adults.
     Cogn Behav Ther, 39(4): 283-92. [Abstract] [Full-text]
119. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy.
     Arch Gynecol Obstet. [Abstract] [Full-text]
120. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
     Pharmacol Biochem Behav. [Abstract] [Full-text]
121. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences.
     Psychiatry Res, 191(1): 51-9. [Abstract] [Full-text]
122. Pain-related anxiety and marijuana use motives: a pilot test among active marijuana-using young adults.
     Cogn Behav Ther, 39(4): 283-92. [Abstract] [Full-text]
123. Adolescent substance abuse: the effects of alcohol and marijuana on neuropsychological performance.
     Alcohol Clin Exp Res, 35(1): 39-46. [Abstract] [Full-text]
124. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy.
     Arch Gynecol Obstet. [Abstract] [Full-text]
125. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
     Pharmacol Biochem Behav. [Abstract] [Full-text]
126. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences.
     Psychiatry Res, 191(1): 51-9. [Abstract] [Full-text]
127. Adolescent substance abuse: the effects of alcohol and marijuana on neuropsychological performance.
     Alcohol Clin Exp Res, 35(1): 39-46. [Abstract] [Full-text]
128. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences.
     Psychiatry Res, 191(1): 51-9. [Abstract] [Full-text]
129. Adolescent substance abuse: the effects of alcohol and marijuana on neuropsychological performance.
     Alcohol Clin Exp Res, 35(1): 39-46. [Abstract] [Full-text]
130. Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders.
     Psychiatry Res, 185(1): 205-10. [Abstract] [Full-text]
131. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences.
     Psychiatry Res, 191(1): 51-9. [Abstract] [Full-text]
132. Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders.
     Psychiatry Res, 185(1): 205-10. [Abstract] [Full-text]
133. Poor decision-making by chronic marijuana users is associated with decreased functional responsiveness to negative consequences.
     Psychiatry Res, 191(1): 51-9. [Abstract] [Full-text]
134. Features and prevalence of patients with probable adult attention deficit hyperactivity disorder who request treatment for cocaine use disorders.
     Psychiatry Res, 185(1): 205-10. [Abstract] [Full-text]
135. Acute mutism: a useful lesson.
     Emerg Med J, 28(1): 82-3. [Abstract] [Full-text]
136. Acute mutism: a useful lesson.
     Emerg Med J, 28(1): 82-3. [Abstract] [Full-text]
137. Acute mutism: a useful lesson.
     Emerg Med J, 28(1): 82-3. [Abstract] [Full-text]
138. Regulation of nausea and vomiting by cannabinoids.
     Br J Pharmacol. [Abstract] [Full-text]
139. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
     Br J Pharmacol. [Abstract] [Full-text]
140. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
     J Psychopharmacol, 25(1): 121-30. [Abstract] [Full-text]
141. Regulation of nausea and vomiting by cannabinoids.
     Br J Pharmacol. [Abstract] [Full-text]
142. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
     Br J Pharmacol. [Abstract] [Full-text]
143. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
     J Psychopharmacol, 25(1): 121-30. [Abstract] [Full-text]
144. Regulation of nausea and vomiting by cannabinoids.
     Br J Pharmacol. [Abstract] [Full-text]
145. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
     Br J Pharmacol. [Abstract] [Full-text]
146. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
     J Psychopharmacol, 25(1): 121-30. [Abstract] [Full-text]
147. Mephedrone toxicity in a Scottish emergency department.
     Emerg Med J. [Abstract] [Full-text]
148. An analytical evaluation of eight on-site oral fluid drug screening devices using laboratory confirmation results from oral fluid.
     Forensic Sci Int. [Abstract] [Full-text]
149. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.
     Br J Pharmacol. [Abstract] [Full-text]
150. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
     Psychopharmacology (Berl). [Abstract] [Full-text]
151. Mephedrone toxicity in a Scottish emergency department.
     Emerg Med J. [Abstract] [Full-text]
152. An analytical evaluation of eight on-site oral fluid drug screening devices using laboratory confirmation results from oral fluid.
     Forensic Sci Int. [Abstract] [Full-text]
153. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.
     Br J Pharmacol. [Abstract] [Full-text]
154. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
     Psychopharmacology (Berl). [Abstract] [Full-text]
155. Mephedrone toxicity in a Scottish emergency department.
     Emerg Med J. [Abstract] [Full-text]
156. An analytical evaluation of eight on-site oral fluid drug screening devices using laboratory confirmation results from oral fluid.
     Forensic Sci Int. [Abstract] [Full-text]
157. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.
     Br J Pharmacol. [Abstract] [Full-text]
158. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
     Psychopharmacology (Berl). [Abstract] [Full-text]
159. Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis.
     Schizophr Res. [Abstract] [Full-text]
160. Psychosocial correlates of adolescent marijuana use: Variations by status of marijuana use.
     Addict Behav. [Abstract] [Full-text]
161. A brief marijuana intervention for non-treatment-seeking young adult women.
     J Subst Abuse Treat. [Abstract] [Full-text]
162. Can the Gateway Hypothesis, the Common Liability Model and/or, the Route of Administration Model Predict Initiation of Cannabis Use During Adolescence? A Survival Analysis-The TRAILS Study.
     J Adolesc Health, 48(1): 73-8. [Abstract] [Full-text]
163. Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis.
     Schizophr Res. [Abstract] [Full-text]
164. Psychosocial correlates of adolescent marijuana use: Variations by status of marijuana use.
     Addict Behav. [Abstract] [Full-text]
165. A brief marijuana intervention for non-treatment-seeking young adult women.
     J Subst Abuse Treat. [Abstract] [Full-text]
166. Can the gateway hypothesis, the common liability model and/or, the route of administration model predict initiation of cannabis use during adolescence? A survival analysis--the TRAILS study.
     J Adolesc Health, 48(1): 73-8. [Abstract] [Full-text]
167. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring.
     Neuroscience, 172: 139-52. [Abstract] [Full-text]
168. Pre-morbid Conduct Disorder symptoms are associated with cannabis use among individuals with a first episode of psychosis.
     Schizophr Res. [Abstract] [Full-text]
169. Can the gateway hypothesis, the common liability model and/or, the route of administration model predict initiation of cannabis use during adolescence? A survival analysis--the TRAILS study.
     J Adolesc Health, 48(1): 73-8. [Abstract] [Full-text]
170. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring.
     Neuroscience, 172: 139-52. [Abstract] [Full-text]
171. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring.
     Neuroscience, 172: 139-52. [Abstract] [Full-text]
172. Synaptic neurotransmission depression in ventral tegmental dopamine neurons and cannabinoid-associated addictive learning.
     PLoS One, 5(12): e15634. [Abstract] [Full-text]
173. The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.
     Pharmacol Biochem Behav. [Abstract] [Full-text]
174. Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers.
     Pharmacol Biochem Behav, 97(4): 627-31. [Abstract] [Full-text]
175. Synaptic neurotransmission depression in ventral tegmental dopamine neurons and cannabinoid-associated addictive learning.
     PLoS One, 5(12): e15634. [Abstract] [Full-text]
176. The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.
     Pharmacol Biochem Behav. [Abstract] [Full-text]
177. Synaptic neurotransmission depression in ventral tegmental dopamine neurons and cannabinoid-associated addictive learning.
     PLoS One, 5(12): e15634. [Abstract] [Full-text]
178. Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers.
     Pharmacol Biochem Behav, 97(4): 627-31. [Abstract] [Full-text]
179. Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers.
     Pharmacol Biochem Behav, 97(4): 627-31. [Abstract] [Full-text]
180. Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers.
     Pharmacol Biochem Behav, 97(4): 627-31. [Abstract] [Full-text]
181. Plasma Cannabinoid Pharmacokinetics following Controlled Oral {Delta}9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration.
     Clin Chem, 57(1): 66-75. [Abstract] [Full-text]
182. Plasma cannabinoid pharmacokinetics following controlled oral Delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
     Clin Chem, 57(1): 66-75. [Abstract] [Full-text]
183. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
     Clin Chem, 57(1): 66-75. [Abstract] [Full-text]
184. Benzodiazepines and Sedative-Hypnotics in Blood of Drivers Under the Influence and Their Association With Other Common Illegal Drug Use and National Sales Figures.
     Ther Drug Monit. [Abstract] [Full-text]
185. Quantification of the influence of friends and antisocial behaviour in adolescent consumption of cannabis using the ZINB model and data mining.
     Addict Behav. [Abstract] [Full-text]
186. Epidemiological analysis of doping offences in the professional tennis circuit.
     J Occup Med Toxicol, 5: 30. [Abstract] [Full-text]
187. Quantification of the influence of friends and antisocial behaviour in adolescent consumption of cannabis using the ZINB model and data mining.
     Addict Behav. [Abstract] [Full-text]
188. Epidemiological analysis of doping offences in the professional tennis circuit.
     J Occup Med Toxicol, 5: 30. [Abstract] [Full-text]
189. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
     J Clin Psychopharmacol, 31(1): 86-91. [Abstract] [Full-text]
190. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
     J Clin Psychopharmacol, 31(1): 86-91. [Abstract] [Full-text]
191. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
     J Clin Psychopharmacol, 31(1): 86-91. [Abstract] [Full-text]

© 2004-2011 Marijuana Research Today. All Rights Reserved.